FLGT
What one share of Fulgent Genetics holds
Services – Medical Laboratories
We are a technology-based company with a well-established laboratory services business and a therapeutic development business. Our laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians.
Fulgent Genetics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $10.74 |
|---|---|
| Profit | −$2.80 |
| Capex (buildings and equipment) | $0.67 |
| Free cash flow | −$3.44 |
| Cash and investments | $0.96 |
| Debt | $0.07 |
| Book value | $36.40 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.33 | −$1.00 | $0.28 | $0.04 | — | $3.08 |
| 2017 | $1.06 | −$0.14 | $0.16 | −$0.09 | — | $3.04 |
| 2018 | $1.19 | −$0.31 | $0.13 | −$0.17 | — | $2.81 |
| 2019 | $1.74 | −$0.02 | $0.06 | $0.23 | — | $3.85 |
| 2020 | $17.53 | $8.91 | $1.46 | $4.39 | — | $20.21 |
| 2021 | $32.04 | $16.38 | $0.77 | $16.62 | — | $38.42 |
| 2022 | $19.99 | $4.63 | $0.61 | $7.58 | — | $43.03 |
| 2023 | $9.71 | −$5.63 | $0.75 | $0.16 | — | $38.31 |
| 2024 | $9.38 | −$1.41 | $1.33 | −$0.64 | — | $36.74 |
| 2025 | $10.48 | −$1.97 | $0.73 | −$4.04 | — | $35.78 |